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Background: Acidity is a hallmark of malignant tumor, representing a very efficient mechanism of chemoresistance.
Proton pump inhibitors (PPI) at high dosage have been shown to sensitize chemoresistant human tumor cells and
tumors to cytotoxic molecules. The aim of this pilot study was to investigate the efficacy of PPI in improving the
clinical outcome of docetaxel + cisplatin regimen in patients with metastatic breast cancer (MBC).
Methods: Patients enrolled were randomly assigned to three arms: Arm A, docetaxel 75 mg/m2 followed by
cisplatin 75 mg/m2 on d4, repeated every 21 days with a maximum of 6 cycles; Arm B, the same chemotherapy
preceded by three days esomeprazole (ESOM) 80 mg p.o. bid, beginning on d1 repeated weekly. Weekly
intermittent administration of ESOM (3 days on 4 days off) was maintained up to maximum 66 weeks; Arm C, the
same as Arm B with the only difference being dose of ESOM at 100 mg p.o. bid. The primary endpoint was
response rate.
Results: Ninety-four patients were randomly assigned and underwent at least one injection of chemotherapy. Response
rates for arm A, B and C were 46.9, 71.0, and 64.5 %, respectively. Median TTP for arm A (n= 32), B (n = 31), C (n = 31) were
8.7, 9.4, and 9.7 months, respectively. A significant difference was observed between patients who had taken PPI and who
not with ORR (67.7 % vs. 46.9 %, p = 0.049) and median TTP (9.7 months vs. 8.7 months, p = 0.045). Exploratory analysis
showed that among 15 patients with triple negative breast cancer (TNBC), this difference was bigger with median TTP of
10.7 and 5.8 months, respectively (p = 0.011). PPI combination showed a marked effect on OS as well, while with a
borderline significance (29.9 vs. 19.2 months, p = 0.090). No additional toxicity was observed with PPI.
Conclusions: The results of this pilot clinical trial showed that intermittent high dose PPI enhance the antitumor effects
of chemotherapy in MBC patients without evidence of additional toxicity, which requires urgent validation in a
multicenter, randomized, phase III trial.
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Extracellular acidity is a hallmark of malignant tumors
with a pivotal role in the invasion, metastasis, drug re-
sistance and selection of more aggressive cell phenotypes
armed to survive in very hostile microenvironmental
condition [1–5]. The prime cause of tumor acidity is
the fermentation of the sugars that invariably induce
production of lactate, also called Warburg Effect [6]
(Additional file 1: Figure S1). In addition, some proton-
coupled monocarboxylate transporter (MCT) subtypes
of the SLC16A gene family which rely on CD147, a
chaperone to some MCTs, for expression contribute to
regulate tumor acidity via the monocarboxylate (such as
lactate) symport [7]. One of the most important mech-
anism allowing tumor cells to survive in acidic condition
are some proton exchangers, including the vacuolar
ATPase (V-ATPase). V-ATPase on one hand pump H+
from the cytosol within the internal vesicles, on the
other hand eliminate H+ outside the cells, thus contrib-
uting to extracellular acidification (pHe), and to the cito-
solic alkalinization (pHi) as well; a pathway of reverse
pH gradient that again is a peculiar characteristic of ma-
lignant tumors [8–11]. Tumor cells use proton pumps
to avoid a cascade of lytic enzymes activation that inevit-
ably may lead to self-digestion [9, 12–14]. Pre-clinical
evidence demonstrated that an antiacidic approach
based either on buffering molecules or inhibitors of pro-
ton exchangers may increase the efficacy of chemothera-
peutic agents [1–4, 6, 9, 15]. However, the same
approach may also induce a direct antitumor effect by
inhibiting H+ clearance from tumor cells, leading to
tumor cell death [4, 16–18]. Some further evidence sup-
ports also a role of tumor acidity as a tumor escape
mechanism. In fact, proton pump inhibition increases
the effect of immunotherapy and the spontaneous
anti-tumor immune response [19]. Although these are
features described for a wide spectrum of cancers, extra-
cellular acidity was proven to have a key role in resistance
of breast cancer cells to chemotherapeutics, through an
impairment of drug uptake [20, 21]. In fact, both bicar-
bonate pretreatment and overexpression of Homo sapi-
ens longevity assurance homolog 2 of yeast LAG1
(LASS2) which interacts with VPL (proteolipid subunit
of vacuolar H+ ATPase) increases antitumor activity of
either doxorubicin or mitoxantrone, in a mouse breast
tumor model [22, 23]. More recent evidence suggests
that V-ATPase inhibition induces cell death and growth
inhibition in trastuzumab-resistant breast cancer cells,
through a HER-2-mediated pathway [24]. Knock-down
of the V-ATPase subunit c can also increase sensitivity of
breast cancer cells to various cytotoxic agents, including
cisplatin [15, 25]. Inhibition of proton pumps may re-
establish a pH-gradient more suitable for both the uptake
and the retention of various antitumor drugs with cancercells, as it has been shown for the V-ATPase inhibitor bafi-
lomycin, in the case of cisplatin as well [26, 27]. However,
a direct V-ATPase inhibition through bafilomycin
showed high level of systemic toxicity, due to the ubi-
quitous distribution of these enzymes in normal tissues
[28]. As a consequence, the use of V-ATPase inhibitors,
such as bafilomycin, as either potential anti-tumor
drugs or simply chemosensitizers was abandoned due
to their high level of systemic toxicity and did never get
to phase I clinical trials. However, a class of proton
pump inhibitors (PPIs) including esomeprazole (ESOM),
omeprazole, lansoprazole, pantoprazole and rabeprazole,
currently used in the treatment of peptic diseases,
have been shown to represent a model of drugs with a
high potential in the future anti-cancer strategies [14].
While they have been originally described as specific
blockers of gastric H+-K+ ATPases, they can also in-
hibit V-ATPase activity [4]. PPI have been used by bil-
lions of people worldwide in the last decades, without
significant side effects [29], even at high dosages (as in
patients with Zollinger-Ellison syndrome) [30, 31].
Interestingly, the absence of toxicity for this class of
drug is largely due to their dependence on an acidic
pH for activation, inasmuch as PPI are administered as
prodrugs, either orally or systemically, needing low pH
in order to be transformed into the active compounds
tetracyclic sulfonamide [32]. Thus, for PPI, differently
to the vast majority of the drugs including anticancer
drugs, protonation in an acidic environment leads to
activation instead of neutralization. As lipophilic and
weakly basic prodrugs, they easily penetrate cell mem-
branes and concentrate in acidic compartments, where
they are unstable and are converted into sulfonamide
forms, which are the active inhibitors [33]. Based on
these properties, PPIs have been extensively investi-
gated for their potential to reduce tumor acidity and
overcome the acid related chemoresistance. Further-
more, PPIs could have direct tumor cell toxicity by de-
priving them of a key mechanism for surviving in their
aberrant acidic condition. A number of studies have
now shown that PPIs can be useful in modulating
tumor acidification and restoring chemotherapeutic
sensitivity in drug-resistant cancer cells in in vitro and
in vivo preclinical studies [15, 34–36]. These preclin-
ical data have been supported by clinical studies in
both patients with osteosarcoma [37] and in compan-
ion animals with spontaneous tumors [38, 39]. In
addition, specific cytotoxic effects of PPIs on tumor
cells have been reported, including B cell lymphoma
[40], melanoma [18], pancreatic cancer [36], esopha-
geal cancer [41], gastric carcinoma [42], Ewing sar-
coma [43], osteosarcoma, rhabdomyosarcoma and
chondrosarcoma [37, 44]. As expected, the PPI induced
cytotoxicity is strongly enhance in low pH culture
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models of breast cancer as well at various levels, in-
cluding growth, invasion and metastasis [45–47].
Moreover, long lasting treatment with PPI in patients
with Barrett’s oesophagus significantly reduces the risk
of oesophageal adenocarcinoma and/or high grade dys-
plasia [48, 49].
With this background we set up a pilot, prospective,
randomized, phase II clinical study (NCT01069081) with
the purpose to investigate whether the PPI ESOM might
improve the efficacy of chemotherapy in patients with
metastatic breast cancer (MBC). Cisplatin is moderately
active as first-line treatments in MBC, with an objective
response rate (ORR) 40 to 60 % [50]. Cisplatin-based
regimens are also widely tested in the first-line meta-
static setting with median time to progression (TTP) of
7.2 to 11.7 months and acceptable toxicities [51–56].
Based on these data and sufficient experience of our
center [56–58], the doublet TP regimen (docetaxel and
cisplatin combination) was an acceptable option for the
control arm and suitable for this proof of concept set-
ting. In the setup of the treatment combining the TP
regimen with ESOM we use 3 key criteria: (i) two fixed
doses of 160 and 200 mg/day were established based on
the pre-clinical evidence of ESOM [18]; (ii) pretreatmentFig. 1 Study designwith ESOM, based on the pre-clinical evidence that only
pre-treatment showed to increase chemosensitization
[15]; and (iii) the intermittent schedule, based both on
the rationale that an acidic pH is needed for a full PPI
activation, in order to be transformed into the active
molecule (sulfonamide) and on the in vivo evidence
showing that tumor pHe is PPI-dependent, showing dis-
played an initial shift towards neutrality after ESOM
treatment, returning to acidic values within 48 h after
the stop of the treatment [18]; we thus used a weekly
treatment schedule of consecutive 3 days of a full ESOM
dosage, followed by 4 days ESOM off immediately
followed by TP regimen-based chemotherapy.
Materials and methods
Patients
Women age ≥ 18 years with histologically confirmed, recur-
rent or metastatic breast cancer were eligible. Neoadjuvant/
adjuvant paclitaxel treatment was permitted, while doce-
taxel was permitted only if patients were disease free for ≥
12 months after chemotherapy. Patients were required to
have a Karnofsky performance status (KPS) of 60 or greater,
life expectancy of ≥ 3 months, measurable disease per Re-
sponse Evaluation Criteria in Solid Tumors (RECIST) v1.0,
and adequate organ function. If Her-2 was positive, only
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ered by insurance in China) can be included. For lu-
minal subtype, only those with more rapid relapse or
visceral metastases were included. Main exclusion cri-
teria included brain metastases, prior chemotherapy in
the metastatic setting or inability to swallow capsules.
Prior hormonal treatment was allowed but must be dis-
continued 14 days prior to study entry.
Ethics, consent and permissions
The study was conducted in accordance with the Inter-
national Conference on Harmonisation Good Clinical
Practice guidelines, the Declaration of Helsinki, and
applicable local regulatory requirements and laws.
Study procedures were approved by institutional eth-
ical board of FUSCC. Written informed consent was
obtained from all patients.
Study design and treatment
This was a randomized open-label phase II study. The
primary endpoint was response rate. Secondary end-
points included TTP, overall survival (OS), and safetyFig. 2 Consort diagramprofile. The safety endpoint was the incidence of adverse
events (AEs) and changes in laboratory values. Patients
were randomly assigned in a 1: 1: 1 ratio, with no strati-
fication factors, to three treatment arms: docetaxel and
cisplatin (arm A), docetaxel and cisplatin with lower
dose ESOM (80 mg p.o. bid, 3 days on and 4 days off;
arm B), or docetaxel and cisplatin with higher dose
ESOM (100 mg p.o. bid, 3 days on and 4 days off; arm
C) (Fig. 1). For these patients, docetaxel was adminis-
tered at 75 mg/m2 over 60 min and followed by cisplatin
at 75 mg/m2 on day 4 every 3 weeks for a maximum of
six cycles. Intravenous hydration was given on days 3 to
5 with close monitoring of both renal function and urine
output of at least 2000 ml per day. Primary prophylaxis
with G-CSF or antibiotics was prohibited. In the two
ESOM arms, ESOM was administered during the three
days preceding chemotherapy and continued thereafter
for up to 66 weeks, until disease progression, death,
withdrawal of informed consent, or unacceptable tox-
icity. Doses of study drugs could be reduced or with-
held up to 14 days, following protocol-specified rules,
if patients experienced toxicity. Treatment should be
Table 1 Patient characteristics of the 94 patients with metastatic breast cancer receiving first line docetaxel + cisplatin combination
chemotherapy +/- the protone pump inhibitor esomeprazole
Whole population
(n = 94)
Arm A (no ESOM)
(n = 32)
Arm B (lower dose ESOM)
(n = 31)
Arm C (higher dose ESOM)
(n = 31)
Median Age (years) 52 (31-67) 52 (31-66) 50 (36-64) 54 (33-67)
Amenorrhea
Premenopausal 30 (31.9 %) 10 (31.3 %) 11 (35.5 %) 9 (29.0 %)
Postmenopausal 64 (68.1 %) 22 (68.8 %) 20 (64.5 %) 22 (71.0 %)
Advanced or metastatic
de novo metastatic 8 (8.5 %) 1 (3.1 %) 4 (12.9 %) 3 (9.7 %)
Metastatic 86 (91.5 %) 31 (96.9 %) 27 (87.1 %) 28 (90.3 %)
Median DFI (years) 3.3 3.2 3.2 3.4
No. of metastatic sites
1 23 (24.5 %) 10 (31.3 %) 6 (19.4 %) 7 (22.6 %)
2 37 (39.4 %) 9 (28.1 %) 15 (48.4 %) 13 (41.9 %)
≥3 34 (36.2 %) 13 (40.6 %) 10 (32.3 %) 11 (35.5 %)
Metastatic sites
Visceral 69 (73.4 %) 25 (78.1 %) 22 (71.0 %) 22 (71.0 %)
Lung 50 (53.2 %) 18 (56.3 %) 16 (51.6 %) 16 (51.6 %)
Liver 39 (41.5 %) 15 (46.9 %) 11 (35.5 %) 13 (41.9 %)
Nonvisceral 25 (26.6 %) 7 (21.9 %) 9 (29.0 %) 9 (29.0 %)
Bone 38 (40.4 %) 10 (31.3 %) 15 (48.4 %) 13 (41.9 %)
ER status
Positive 61 (64.9 %) 19 (59.4 %) 22 (71.0 %) 20 (64.5 %)
Negative 33 (35.1 %) 13 (40.6 %) 9 (29.0 %) 11 (35.5 %)
PR status
Positive 57 (60.6 %) 20 (62.5 %) 18 (58.1 %) 19 (61.3 %)
Negative 37 (39.4 %) 12 (37.5 %) 13 (41.9 %) 12 (38.7 %)
HER-2 status
Positive 15 (16.0 %) 4 (12.5 %) 5 (16.1 %) 6 (19.4 %)
Negative 79 (84.0 %) 28 (87.5 %) 26 (83.9 %) 25 (80.6 %)
Prior chemotherapy
Adjuvant/neoadjuvant
Anthracyclines only 34 (36.2 %) 12 (37.5 %) 11 (35.5 %) 11 (35.5 %)
Taxanes only 2 (2.1 %) 0 (0 %) 1 (3.2 %) 1 (3.2 %)
Both antracyclines and taxanes 41 (43.6 %) 16 (50.0 %) 12 (38.7 %) 13 (41.9 %)
others 6 (6.4 %) 0 (0 %) 3 (9.7 %) 2 (6.5 %)
None 11 (11.7 %) 4 (12.5 %) 4 (12.9 %) 4 (12.9 %)
Prior endocrine therapy
1 44 (46.8 %) 15 (46.9 %) 13 (41.9 %) 16 (51.6 %)
2 19 (20.2 %) 5 (15.6 %) 9 (29.0 %) 5 (16.1 %)
≥3 5 (5.3 %) 2 (6.3 %) 2 (6.5 %) 1 (3.2 %)
None 26 (27.7 %) 10 (31.3 %) 7 (22.6 %) 9 (29.0 %)
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Table 1 Patient characteristics of the 94 patients with metastatic breast cancer receiving first line docetaxel + cisplatin combination
chemotherapy +/- the protone pump inhibitor esomeprazole (Continued)
Subgroup
Triple negative 15 (16.0 %) 7 (21.9 %) 2 (6.5 %) 6 (19.4 %)
Her-2 positive 11 (11.7 %) 3 (9.4 %) 5 (16.1 %) 3 (9.7 %)
Luminal Type 68 (72.3 %) 22 (68.8) 24 (77.4) 22 (71.0)
ESOM esomeprazole, DFI disease free survival; de novo metastatic: metastatic breast cancer is diagnosed when there is no prior history of breast cancer
Demographic and baseline disease characteristics of the intention-to-treat population were generally well balanced between treatment arms (all p > 0.05)
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greater than twice was required.
Both two separate efficacy analyses of each experimental
arm (arm B and C) and the two experimental arms com-
bined together versus the control arm (arm A) were
planned. Tumor assessment was performed by investigators
using computed tomography (CT), spiral CT, or magnetic
resonance imaging (MRI) at baseline and every two cycles
during chemotherapy until disease progression or death ac-
cording to the RECIST 1.0, and every three months after
discontinuation of chemotherapy. Safety was assessed each
cycle; AEs were graded using National Cancer Institute
Common Terminology Criteria for Adverse Events version
3.0. Adverse event data were collected up to 28 days after
the last dose of study medication.
Statistics analysis
The trial design is a randomized phase II screening design
that provides a non-definitive, screening comparison of
TP + ESOM against TP. Several authors advocated for such
a design for screening promising regimens and detecting
reasonably sized efficacy differences between arms at a
slightly inflated type I error [59, 60]. The primary objective
was to compare the ORR of the experimental regimen to
the ORR of control arm using a one-sided log-rank test
with a significance level of p = 0.15 and find out if one (B or
C) or both of the investigational arms (B and C) might pro-
vide higher ORR and would be worthy of further investiga-
tion. When the study was designed, the expected ORR of
TP regimen was 42 % (similar to the ORR of [61]). To de-
tect an absolute difference of 23 % in ORR between groups
with a power of 80 % and an inflated one-sided significance
level at 0.15, at least 30 patients were needed in each group.
TTP was defined as the time from patient randomization
until objective tumor progression using RECIST 1.0 criteria.
OS was defined as time between enrollment and the dates
of death from any cause or last follow-up. The intent-to-
treat population was all patients randomized. Treatment ef-
ficacy and safety were evaluated in all patients who received
at least one dose of study medication (as-treated popula-
tion). Time-to-event endpoints (TTP and OS) were calcu-
lated using the Kaplan-Meier method. Between-treatment
comparisons were conducted using two-sided log-rank
tests, and therefore, α = .05 overall significance level wasused. Cox’s proportional hazard model was used to define
independent prognostic factors for OS. Between-treatment
comparisons of the ORR and frequencies of AEs on treat-
ment were performed post hoc using the χ2 test.
Results
Baseline characteristics
From Aug. 2009 to Aug. 2011, 100 women signed in-
formed consent form (ICF) and 94 were randomly
assigned and formed the intention-to-treat (ITT)
population (Fig. 2). All the eligible patients underwent
at least one injection of chemotherapy and were in-
cluded in the safety analyses. Demographic and base-
line disease characteristics of the ITT population were
generally well balanced between treatment arms (all
p > 0.05) (Table 1).
Treatment exposure
The median duration of ESOM administration was
33 weeks in the arm B (ESOM 80 mg p.o. bid) and 30 weeks
in the arm C (ESOM 100 mg p.o. bid). TP regimen was
given at a median of 6 cycles in all the three arms and the
relative dose intensity delivered was similar in all the three
arms (Additional file 2: Table S1).
The major reasons for stopping TP chemotherapy in-
cluded completion of protocol-defined 6 cycles of
treatments (56.3 % of arm A, 80.6 % of arm B, and
71.0 % of arm C), disease progression during chemo-
therapy (25.0 % of arm A, 12.9 % of arm B, and 16.1 %
of arm C), and adverse event (12.5 % of arm A, 0 % of
arm B, and 6.5 % of arm C). It appeared clear that high
dosage ESOM reduced the percentage of disease pro-
gression without additional occurrence of adverse
events. In fact, the statistical analysis showed that sig-
nificantly more patients completed treatment cycles in
arms B and C (p = 0.037) (Fig. 2).
Subsequent treatments after TP regimen including endo-
crine therapy and chemotherapy showed no statistically sig-
nificant differences among three arms (Additional file 3:
Table S2).
Efficacy
The results in the arm A patients confirmed the efficacy
of the TP combination regimen in the first-line setting
Fig. 3 (See legend on next page.)
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Fig. 3 a Kaplan-Meier curve for Time to progression (TTP) in breast cancer patients with or without ESOM. Median TTP in patients with or without
ESOM were 9.7 months and 8.7 months respectively. (HR 0.626, 95 % CI 0.394-0.995, p = 0.045). b Kaplan-Meier curve for Overall survival (OS) in
breast cancer patients with or without ESOM. Median OS in patients with or without ESOM were 29.9 months and 19.2 months respectively.
(HR 0.634, 95 % CI 0.373-1.079, p = 0.090). c Kaplan-Meier curve for Time to progression (TTP) in metastatic TNBC patients with or without ESOM.
Median TTP in patients with or without ESOM were 10.7 months and 5.8 months respectively. (HR 0.020, 95 % CI 0.048-0.772, p = 0.011)







Arm A (no ESOM)
(n = 32)
46.9 8.7 (6.8-10.6) 19.2 (10.1-28.3)
Arm B (lower dose ESOM
(n = 31)
71.0 9.4 (5.8-13.1) 39.3 (31.6-47.1)
Arm C (higher dose
ESOM (n = 31)
64.5 9.7 (7.8-11.6) 26.1 (21.1-31.1)
Arm B + C (Combined
(n = 62)
67.7 9.7 (7.6-11.8) 29.9 (22.3-37.4)
ESOM esomeprazole, ORR overall response rate, mTTP median time to
progression, mOS median over survival
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8.7 months, and acceptable toxicities. The efficacy was
comparable to paclitaxel/gemcitabine (ORR 41.4 %, TTP
6.1 months) [62] and docetaxel/capecitabine (ORR
42.0 %, TTP 6.1 months) [61].
After a median follow up of 40 months, 84 (89.4 %) pa-
tients got disease progression and 59 (62.8 %) patients died.
The analysis of the results aimed at exploring the primary
endpoint of the study, i.e. the ORR, showed that the ORR
for arm A (n = 32), arm B (n = 31), arm C (n = 31) were
46.9, 71.0, and 64.5 %, respectively. No statistical differ-
ences of ORR were shown between arm B (p = 0.052) or C
(p = 0.159) and A. As planned, we compared the pool of
patients receiving PPI to those treated exclusively with
chemotherapy and the statistical analysis showed a signifi-
cant difference in term of ORR between patients who
received PPI, as compared to those treated with chemo-
therapy alone (67.7 vs. 46.9 %, p = 0.049). We analyzed fur-
ther the data in term of median TTP. The results were 8.7,
9.4, and 9.7 months, for arm A (n = 32), arm B (n = 31),
arm C (n = 31) respectively and no statistical differences
were shown between arm B or C and A. When pooling the
two groups (B and C) for the statistical analysis, a signifi-
cant difference was shown between the PPI treated and un-
treated patients in terms of median TTP (9.7 months vs.
8.7 months, p = 0.045, Fig. 3a). If we focusing on the triple
negative breast cancer (TNBC) subgroup (n = 15), the ob-
served differences were even more clear with median TTP
of 10.7 and 5.8 months, respectively (p = 0.011) (Fig. 3c).
The analysis of the treatment effect on OS showed a
marked difference between the two groups (29.9 vs.
19.2 months) while with only a borderline significant in
favor of PPI combination, (p = 0.090) (Fig. 3b and Table 2),
probably due to the small patients’ sample.
Safety
All patients who received at least one dose of TP regi-
men were analyzed for safety. Toxicity profiles of all ad-
verse events for the three regimens are summarized in
Table 3. The most common (>5 % in any arm) grade 3/4
hematologic toxicities were neutropenia, leukopenia, fe-
brile neutropenia, and anemia. The most common (>5 %
in any arm) grade 3/4 non-hematologic toxicities were
nausea, vomiting, hypersensitivity, and diarrhea. Three
patients had severe hypersensitivity reactions, two occur-
ring after the first injection of docetaxel and one in the
second cycle. There were no treatment-related deaths.All toxicities (all grades or grade 3/4) were similar
among three treatment arms (all p > 0.05).
Discussion
This pilot prospective, randomized, phase II trial evalu-
ated the efficacy of ESOM, in association with TP regi-
men, in the first-line treatment of MBC patients. To our
knowledge, this is the first clinical study to test the hy-
pothesis that manipulation of pH gradient in tumor
microenvironment can enhance antitumor effects of
chemotherapy in MBC patients. Our study preliminarily
showed a significant difference in both ORR and TTP
between patients co-treated with ESOM and those who
received exclusively TP regimen. Actually, this result
was achieved not only through a simple addition of
ESOM to the treatment schedule during TP regimen,
but through a continuation of the PPI treatment for up
to 66 weeks, until disease progression, death, withdrawal
of informed consent, or unacceptable toxicity. This, of
course may suggest that the clinical might be due to either
or both the PPI-induced chemosensitization [15, 37–39]
and/or an additional effect due to the direct anti-tumor ac-
tivity of PPI [18, 40]. Independently from any interpretation
of the data, we have shown for the first time a potential
synergistic effect of repeating intermittent high dose of PPI
with a standard chemotherapeutic regimen based on cis-
platin and docetaxel in patients with MBC, which is worthy
of being validated in future phase III trial. Although with a
comparable median TTP, the dose level with 80 mg bid
showed a relatively higher ORR (primary endpoint) and
median OS than the dose level with 100 mg bid. The rela-
tively longer OS in lower dose arm can be partly attributed
Table 3 Toxicities (n = 94)
Whole population Arm A (n = 32) Arm B (n = 31) Arm C (n = 31)
Toxicity (%) All grade Grade 3/4 All grade Grade 3/4 All grade Grade 3/4 All grade Grade 3/4
Hematologic
Neutropenia 86 (91.5) 79 (84.0) 29 (90.6) 26 (81.3) 30 (96.8) 27 (87.0) 27 (87.1) 26 (83.9)
Leukopenia 86 (91.5) 61 (64.9) 28 (87.5) 20 (62.5) 30 (96.8) 23 (74.2) 28 (90.3) 18 (58.1)
Thrombocytopenia 17 (18.1) 1 (1.1) 6 (18.8) 0 5 (16.1) 1 (3.2) 6 (19.4) 0
Anemia 56 (59.6) 5 (5.3) 15 (46.9) 0 20 (64.5) 3 (9.7) 21 (67.7) 2 (6.5)
Febrile neutropenia 18 (19.1) 18 (19.1) 6 (18.8) 6 (18.8) 5 (16.1) 5 (16.1) 7 (22.6) 7 (22.6)
Non-hematologic
Hypersensitivity 3 (3.2) 3 (3.2) 2 (6.3) 2 (6.3) 0 0 1 (3.2) 1 (3.2)
Rash 3 (3.2) 0 0 0 1 (3.2) 0 2 (3.3) 0
Peripheral neuropathy 40 (42.6) 2 (2.1) 13 (40.6) 0 13 (41.9) 1 (3.2) 14 (45.2) 1 (3.2)
Alopecia 37 (39.4) 0 12 (37.5) 0 12 (38.7) 0 13 (41.9) 0
Fatigue 47 (50.0) 0 17 (53.1) 0 16 (51.6) 0 14 (45.2) 0
Nausea 49 (52.1) 3 (3.2) 15 (46.9) 0 18 (58.0) 0 16 (51.6) 3 (9.7)
Vomiting 44 (46.8) 3 (3.2) 16 (50.0) 0 12 (38.7) 0 16 (51.6) 3 (9.7)
Diarrhea 28 (29.8) 2 (2.1) 8 (25.0) 0 8 (25.8) 2 (6.5) 12 (38.7) 0
Constipation 14 (14.9) 0 5 (15.6) 0 6 (19.4) 0 3 (9.7) 0
Liver dysfunction 5 (5.3) 0 1 (3.1) 0 3 (9.7) 0 1 (3.2) 0
Renal dysfunction 1 (1.1) 0 0 0 1 (3.2) 0 0 0
Mucositis 3 (3.2) 0 1 (3.1) 0 1 (3.2) 0 1 (3.2) 0
Abdominal pain 14 (14.9) 0 3 (9.4) 0 3 (9.7) 0 8 (25.8) 0
Stomach discomfort 2 (2.1) 0 0 0 2 (6.5) 0 0 0
Abdominal discomfort 2 (2.1) 1 (1.1) 1 (3.1) 1 (3.1) 1 (3.2) 0 0 0
Loss of appetite 46 (48.9) 2 (2.1) 14 (43.8) 1 (3.1) 17 (54.8) 0 15 (48.4) 1 (3.2)
Hyperpigmentation 2 (2.1) 0 0 0 2 (6.5) 0 0 0
Edema 6 (6.4) 1 (1.1) 3 (9.4) 1 (3.1) 2 (6.5) 0 1 (3.2) 0
Dizziness 12 (12.8) 0 4 (12.5) 0 4 (12.9) 0 4 (12.9) 1 (3.2)
Myalgia and Arthralgia 7 (7.4) 0 1 (3.1) 0 2 (6.5) 0 4 (12.9) 0
Insomia 4 (4.3) 0 3 (9.4) 0 0 0 1 (3.2) 0
Dyspnea 4 (4.3) 0 2 (6.3) 0 2 (6.5) 0 0 0
Delacrimation 1 (1.1) 0 0 0 0 0 1 (3.2) 0
Blurred vision 1 (1.1) 0 0 0 1 (3.2) 0 0 0
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(Additional file 3: Table S2). Taking into consideration
the cost, risk and benefit, the dose level with 80 mg bid
is recommended for phase III testing. Recently, significantly
stronger immunofluorescence expression of H+/K+ -ATPase
proton pump was observed with the triple negative
MDA-MB-468 cells compared to control MCF-10A cells,
which was confirmed with Western blotting. Differences
in sensitivity to ESOM were also detected in these two cell
lines, with MDA-MB-468 cells found to be significantly
more sensitive [46]. In our study, the effects of TTP were
even more significant when TNBC patients were analyzed
separately, indicating that ESOM has potentially improvedthe prognosis of TNBC patients which was consistent
with the preclinical research [46], although in a small
sample size (15 patients) (Fig. 3c).
Development of resistance to cisplatin is a major
obstacle in the clinical treatment of some solid tumors,
including TNBC [63] and ovarian cancer [64]. Cis-
platin resistance is thought to involve several mecha-
nisms, such as increased drug efflux and cellular thiols
[65, 66] and increased DNA-repair activity [67, 68].
We have recently shown that particularly cisplatin re-
sistance of human malignant tumors may be the result
of both tumor acidity [15, 27] and the release of nano-
vesicles called exosome [69]. In turn, also exosome
Wang et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:85 Page 10 of 12release from cancer cells is highly increased by environ-
mental acidity and proton pump inhibitors or buffering
procedure dramatically inhibit exosomes production by
cancer cells [70]. Notably, exosome plasmatic levels directly
correlate with the tumor size or mass [71], and PPI treat-
ment markedly reduces the plasmatic levels of exosome re-
leased by human tumors in xenograft models [69]. PPI,
together with inducing chemosensitization in both pre-
clinical settings [15, 69] and clinical investigations in both
humans [37] and domestic animals with spontaneous tu-
mors [38, 39] can induce apoptosis in various tumor cell
types and tumors [18, 40, 42], including breast cancer cells
in which PPI inhibit both growth [46] and invasion and me-
tastasis [47].
Actually, our study is the first providing the prelim-
inary clinical proof of concept that PPI may induce
chemosensitization but also contributing to control
tumor progression in breast cancer patients. Recently,
the effectiveness of PPI in improving chemotherapy
was shown in a clinical study on osteosarcoma patients
[37], thus supporting the results of the present study.
Notably, PPI treatment was continued after the stop of
chemotherapy without any evidence of additional or
specific toxicity, suggesting that PPI may well be used
in a chronic treatment of breast cancer patients with
the aim to either prevent disease relapses or control-
ling the disease progression.Conclusions
In conclusion, our trial is the first study that prospect-
ively evaluates the potential use of PPI in treatment of
breast cancer patients. The preliminary results provide
the evidence that intermittent high dose PPI enhances
the antitumor effects of chemotherapy in MBC patients
without evidence of additional toxicity, in term of both
ORR and TTP. Taking into consideration the cost, risk
and benefit, the dose level with 80 mg bid is recom-
mended for phase III testing. Moreover, the PPI treat-
ment was proven particularly efficient in prolonging the
TTP in the subgroup of TNBC, which unfortunately
have currently very poor treatment option. The results
of this pilot clinical trial support the setup of a larger-
sample, multicenter, randomized, phase III clinical trial,
in order to provide a definitive validation for the use of
PPI in future strategy against breast cancer, and hope-
fully other poorly treatable cancer.Additional files
Additional file 1: Figure S1. Warburg Effect. Most cancer cells
predominantly produce energy through a high rate of glycolysis followed
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